MCID: ATR057
MIFTS: 55

Atrioventricular Block

Categories: Cardiovascular diseases

Aliases & Classifications for Atrioventricular Block

MalaCards integrated aliases for Atrioventricular Block:

Name: Atrioventricular Block 12 29 54 6 43 15 71
Av Block 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050820
ICD9CM 34 426.10
MeSH 43 D054537
NCIt 49 C26703
SNOMED-CT 67 58547007
ICD10 32 I44.3 I44.30
UMLS 71 C0004245

Summaries for Atrioventricular Block

Disease Ontology : 12 A heart conduction disease that is characterized by the impairment of the conduction between the atria and ventricles of the heart.

MalaCards based summary : Atrioventricular Block, also known as av block, is related to first-degree atrioventricular block and second-degree atrioventricular block. An important gene associated with Atrioventricular Block is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Nebivolol and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include heart, atrioventricular node and testes, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 74 Atrioventricular block (AV block) is a type of heart block that occurs when the electrical signal... more...

Related Diseases for Atrioventricular Block

Diseases related to Atrioventricular Block via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 514)
# Related Disease Score Top Affiliating Genes
1 first-degree atrioventricular block 34.9 SCN5A MYH7 LMNA CA5B
2 second-degree atrioventricular block 34.4 TRIM21 SSB SCN5A HCN4 CA5B
3 third-degree atrioventricular block 34.1 TTN TRIM21 SSB SCN5A NPPB HCN4
4 progressive familial heart block, type ia 33.4 SCN5A SCN1A MYH7
5 progressive familial heart block 32.5 TRPM4 SCN5A NKX2-5 KCNQ1
6 syncope 32.1 TTN SCN5A KCNQ1 KCNH2
7 progressive familial heart block, type ib 31.6 TRPM4 SCN5A
8 sick sinus syndrome 31.6 TTN SCN5A LMNA HCN4
9 left bundle branch hemiblock 31.5 SCN5A PIK3C2A NPPB LMNA
10 inferior myocardial infarction 31.4 PIK3C2A NPPB CA5B
11 mitral valve insufficiency 31.3 TBX5 NPPB MYH7
12 cardiac conduction defect 31.2 SCN5A MYH7 LMNA KCNQ1 KCNH2
13 heart septal defect 31.2 TBX5 NKX2-5 MYH7 GATA4 CA5B
14 right bundle branch block 31.2 TRPM4 SCN5A NPPB KCNH2 HCN4 CA5B
15 ventricular septal defect 31.1 TBX5 NPPB NKX2-5 MYH7 GATA4
16 ventricular fibrillation, paroxysmal familial, 1 31.1 SCN5A NKX2-5 KCNQ1 KCNH2 KCNE2 KCNE1
17 dextro-looped transposition of the great arteries 31.0 TBX5 NPPB NKX2-5 GATA4
18 atrial standstill 1 31.0 TTN SCN5A NPPB MYH7 LMNA GATA4
19 familial long qt syndrome 31.0 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
20 hypokalemia 31.0 PIK3C2A KCNQ1 KCNH2
21 hypertrophic cardiomyopathy 30.9 TTN SCN5A MYH7 LMNA HCN4 CRYAB
22 atrial heart septal defect 30.8 TTN TBX5 SCN5A NPPB NKX2-5 MYH7
23 tricuspid atresia 30.8 TBX5 NKX2-5 GATA4
24 sinoatrial node disease 30.7 TBX5 SCN5A NKX2-5 KCNQ1 KCNH2 KCNE2
25 heart valve disease 30.7 NPPB NKX2-5 MYH7 GATA4
26 rare cardiomyopathy 30.7 TTN MYH7 LMNA
27 cardiac arrhythmia 30.7 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
28 coronary artery anomaly 30.6 SCN5A PIK3C2A NPPB NKX2-5 KCNH2 GATA4
29 muscular dystrophy 30.5 TTN PIK3C2A NKX2-5 MYH7 LMNA CRYAB
30 restrictive cardiomyopathy 30.5 TTN TRPM4 NPPB MYH7 LMNA CRYAB
31 peripartum cardiomyopathy 30.4 TTN SCN5A MYH7
32 congestive heart failure 30.4 TTN SCN5A PIK3C2A NPPB MYH7 KCNQ1
33 patent ductus arteriosus 1 30.4 TBX5 NPPB NKX2-5 GATA4
34 hypoplastic left heart syndrome 30.4 TBX5 NPPB NKX2-5 MYH7 GATA4
35 long qt syndrome 30.4 TTN TRPM4 SCN5A MYH7 LMNA KCNQ1
36 long qt syndrome 3 30.4 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
37 endocardial fibroelastosis 30.3 TRIM21 SSB NPPB MYH7 CA5B
38 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 30.3 SCN5A MYH7 KCNQ1 KCNH2
39 cardiac arrest 30.3 TTN TRPM4 SCN5A PIK3C2A NPPB MYH7
40 double outlet right ventricle 30.3 TBX5 NKX2-5 GATA4
41 aortic valve disease 1 30.3 TBX5 NKX2-5 HCN4 GATA4
42 atrioventricular septal defect 30.3 TBX5 NKX2-5 GATA4
43 aortic valve disease 2 30.3 TTN TBX5 NPPB NKX2-5 MYH7 GATA4
44 respiratory failure 30.3 TTN PIK3C2A NPPB MYH7 GATA4
45 wolff-parkinson-white syndrome 30.2 TBX5 SCN5A NPPB NKX2-5 MYH7 KCNQ1
46 miyoshi muscular dystrophy 30.2 TTN PIK3C2A MYH7
47 atrial fibrillation 30.1 TTN TBX5 SCN5A NPPB MYH7 LMNA
48 jervell and lange-nielsen syndrome 1 30.1 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
49 neuromuscular disease 30.1 TTN SCN5A MYH7 LMNA CRYAB
50 long qt syndrome 2 30.1 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1

Comorbidity relations with Atrioventricular Block via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Aortic Valve Disease 1
Deficiency Anemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Mitral Valve Disease Right Bundle Branch Block
Sinoatrial Node Disease Third-Degree Atrioventricular Block
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Atrioventricular Block:



Diseases related to Atrioventricular Block

Symptoms & Phenotypes for Atrioventricular Block

MGI Mouse Phenotypes related to Atrioventricular Block:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 GATA4 HCN4 KCNH2 KCNQ1 LMNA MYH7
2 growth/size/body region MP:0005378 10.1 CA5B GATA4 KCNE2 KCNH2 KCNQ1 LMNA
3 homeostasis/metabolism MP:0005376 10.1 CA5B CRYAB GATA4 KCNE2 KCNH2 KCNQ1
4 mortality/aging MP:0010768 10 CA5B GATA4 HCN4 KCNH2 LMNA MYH7
5 muscle MP:0005369 9.7 CRYAB GATA4 HCN4 KCNH2 KCNQ1 LMNA
6 normal MP:0002873 9.32 GATA4 HCN4 KCNQ1 LMNA MYH7 NKX2-5

Drugs & Therapeutics for Atrioventricular Block

Drugs for Atrioventricular Block (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
5
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
7
Enalaprilat Approved Phase 4 76420-72-9 6917719
8
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
9
tannic acid Approved Phase 4 1401-55-4
10
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
11
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
12
Bisoprolol Approved Phase 4 66722-44-9 2405
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Ticagrelor Approved Phase 4 274693-27-5 9871419
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
18
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
19
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
20
Ramipril Approved Phase 4 87333-19-5 5362129
21
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
22
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
23
Remifentanil Approved Phase 4 132875-61-7 60815
24
Pseudoephedrine Approved Phase 4 90-82-4 7028
25
Ephedrine Approved Phase 4 299-42-3 9294
26
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
27
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
28
Procainamide Approved Phase 4 51-06-9 4913
29
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
30
Choline Approved, Nutraceutical Phase 4 62-49-7 305
31 Adrenergic beta-Agonists Phase 4
32 Angiotensin II Type 1 Receptor Blockers Phase 4
33 Giapreza Phase 4
34 Sodium Chloride Symporter Inhibitors Phase 4
35 Angiotensinogen Phase 4
36 Hormone Antagonists Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Hormones Phase 4
39 Analgesics Phase 4
40 Anesthetics Phase 4
41 Calcium, Dietary Phase 4
42 calcium channel blockers Phase 4
43 Adrenergic Agonists Phase 4
44 Hypnotics and Sedatives Phase 4
45 Adrenergic alpha-2 Receptor Agonists Phase 4
46 Anesthetics, General Phase 4
47 Analgesics, Non-Narcotic Phase 4
48 Anesthetics, Intravenous Phase 4
49 Nootropic Agents Phase 4
50 Cytidine Diphosphate Choline Phase 4

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
2 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
3 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4
4 IntAct, Study on Promotion of Intrinsic Activity. Unknown status NCT00156741 Phase 4
5 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
6 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
7 Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block Completed NCT01019213 Phase 4
8 CryoCath Freezor CryoAblation Catheter System (CRYOFACTS) Completed NCT00621621 Phase 4
9 Spontaneous Atrio Ventricular Conduction Preservation Completed NCT00655213 Phase 4
10 PreFER MVP for Elective Replacement Completed NCT00293241 Phase 4
11 Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study Completed NCT02248233 Phase 4 Nimodipine;Saline + citicoline
12 A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
13 A Randomized, Double-Blind Comparison Of Dexmedetomidine And Remifentanil For Sedation During Awake Fiberoptic Intubations Completed NCT00349245 Phase 4 Remifentanil;Dexmedetomidine
14 Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease Completed NCT02383771 Phase 4 Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
15 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
16 Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT) Completed NCT02832973 Phase 4 Spironolactone;Furosemide,;Amiloride;Ramipril;Bisoprolol
17 A Comparison Between Right Ventricular Apical Pacing and True Mid-septal Pacing, Verified With Computed Tomography: a Randomized Study Recruiting NCT02412176 Phase 4
18 Randomized Evaluation of Beta Blocker and Angiotensin Converting Enzyme Inhibitor (ACEI) /Angiotensin Receptor Blocker (ARB) Treatment in MINOCA Patients. Recruiting NCT03686696 Phase 4 Beta blocker;ACEI;ARB
19 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
20 Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE Recruiting NCT03566667 Phase 4 Metoprolol;Standard care
21 Effects of Remifentanil on Diastolic and Systolic Function in Patients With Diastolic Dysfunction Not yet recruiting NCT04117009 Phase 4 Remifentanil 2 MG
22 Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study Terminated NCT00383799 Phase 4 iv Amiodarone;iv Procainamide
23 Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock Terminated NCT02668432 Phase 4 Amiodarone
24 Better Pacing - Biventricular Pacing as Alternative Method in Patients With Disturbances of AV Conduction and Preserved LV Function Withdrawn NCT00559143 Phase 4
25 Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing Completed NCT00925691 Phase 3
26 An Assessment of the Echo-guided Optimal Cardiac Resynchronization Therapy in Patients Undergoing 'Ablate And Pace' Therapy for Permanent Atrial Fibrillation Completed NCT00111527 Phase 3
27 A Prospective Canadian Multi-Center Randomized Study; Spontaneous AtrioVEntricular Conduction PReservation Completed NCT01219621 Phase 3
28 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
29 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Completed NCT00319982 Phase 2, Phase 3 Diltiazem;Placebo
30 Safety and Efficacy of Dexmedetomidine in Painless Colonoscopy: a Single-center, Randomized, Single-blind Study Not yet recruiting NCT03892928 Phase 3 Dexmedetomidine group
31 The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome Terminated NCT00236158 Phase 2, Phase 3
32 Safety and Feasibility of the Injectable BL-1040 Implant Unknown status NCT00557531 Phase 1, Phase 2
33 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
34 A Randomised Controlled Trial of Combinating an Immune Modulator Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke Unknown status NCT02956200 Phase 2 Fingolimod
35 Ablation of Paroxysmal Atrial Fibrillation Using the Appropriate Contact Force in a Chinese Population: A Prospective Randomized Single-center Trial Unknown status NCT02493075 Phase 1, Phase 2
36 Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial Completed NCT00520247 Phase 2 enalapril plus folic acid
37 Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery Completed NCT02498769 Phase 1, Phase 2 Botulinum Toxin Type A;Placebo
38 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
39 A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH) Recruiting NCT03338998 Phase 2 BAF312;Placebo
40 Adjunctive GP Ablation In Redo-PVI: Paroxysmal Atrial Arrhythmias After Pulmonary Vein Isolation Are Driven By Ectopy-Triggering Left Atrial Ganglionated Plexus Recruiting NCT03535818 Phase 2
41 Micra Atrial Tracking Using a Ventricular Accelerometer Study Completed NCT03157297 Phase 1
42 Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction Completed NCT02795637 Phase 1 dasotraline
43 Prospective Analysis of Low-Dose Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart Completed NCT02462941 Phase 1 Adenosine
44 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects Completed NCT01650649 Phase 1 Lofexidine HCl;Lofexidine-matching sugar pill
45 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Buprenorphine-Maintained Adult Subjects Completed NCT01820442 Phase 1 Lofexidine HCl;Lofexidine-matching sugar pill
46 Cohort Description of Younger With AV-block Unknown status NCT03024047
47 Left Ventricular Function and Remodelling During Permanent Pacing Unknown status NCT00228241
48 Minimizing Right Ventricular Pacing in Dual-chamber Pacemaker Patients With Sinus Node Disease and First Degree Atrioventricular Block. Unknown status NCT01611389
49 Observation of ImageReady™ MR Conditional Pacing System in China Unknown status NCT02636712
50 Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms Unknown status NCT02881671

Search NIH Clinical Center for Atrioventricular Block

Cochrane evidence based reviews: atrioventricular block

Genetic Tests for Atrioventricular Block

Genetic tests related to Atrioventricular Block:

# Genetic test Affiliating Genes
1 Atrioventricular Block 29

Anatomical Context for Atrioventricular Block

MalaCards organs/tissues related to Atrioventricular Block:

40
Heart, Atrioventricular Node, Testes, Lung, Kidney, Liver, Brain

Publications for Atrioventricular Block

Articles related to Atrioventricular Block:

(show top 50) (show all 9956)
# Title Authors PMID Year
1
Identification of a new lamin A/C mutation in a Chinese family affected with atrioventricular block as the prominent phenotype. 54 61
20155465 2010
2
Slow progressive conduction and contraction defects in loss of Nkx2-5 mice after cardiomyocyte terminal differentiation. 54 61
19546853 2009
3
Lamin A/C gene mutations in familial cardiomyopathy with advanced atrioventricular block and arrhythmia. 54 61
19638735 2009
4
A novel mutation in LAMIN A/C is associated with isolated early-onset atrial fibrillation and progressive atrioventricular block followed by cardiomyopathy and sudden cardiac death. 54 61
19328042 2009
5
Plasma levels of B-type natriuretic peptide in children and adolescents with high degree atrioventricular block. 54 61
18485504 2009
6
Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy. 54 61
19808398 2008
7
Novel point mutation in the NKX2-5 gene in a Moroccan family with atrioventricular conduction disturbance and an atrial septal defect in the oval fossa. 54 61
17184575 2007
8
Effect of right ventricular apex pacing on the Tei index and brain natriuretic peptide in patients with a dual-chamber pacemaker. 54 61
16981923 2006
9
Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. 54 61
15982494 2005
10
Phenotypes with GATA4 or NKX2.5 mutations in familial atrial septal defect. 54 61
15810002 2005
11
Function follows form: cardiac conduction system defects in Nkx2-5 mutation. 54 61
15368343 2004
12
Biochemical analyses of eight NKX2.5 homeodomain missense mutations causing atrioventricular block and cardiac anomalies. 54 61
15364612 2004
13
[Neonatal forms of congenital long QT syndrome]. 54 61
15214551 2004
14
Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. 54 61
14998624 2004
15
Loss of lamin A/C expression revealed by immuno-electron microscopy in dilated cardiomyopathy with atrioventricular block caused by LMNA gene defects. 54 61
12898247 2003
16
Congenital long QT syndrome and 2:1 atrioventricular block with a mutation of the SCN5A gene. 54 61
12574983 2003
17
Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. 54 61
11897440 2002
18
Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. 54 61
11804990 2002
19
Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. 54 61
11463728 2001
20
Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. 54 61
10587520 1999
21
[Temporal electric stimulation and right ventricular extension in acute postero-inferior myocardial infarction. Influence on clinical characteristics and prognosis]. 54 61
1807297 1991
22
Pacing therapy in children with isolated complete atrioventricular block: a retrospective study of pacing system survival and pacing-related complications in a national cohort. 61
31898724 2020
23
Pacing therapy in children with isolated complete atrioventricular block: a retrospective study of pacing system survival and pacing-related complications in a national cohort-Authors' reply. 61
32031231 2020
24
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. 61
31711921 2020
25
Surgical treatment results of secondary tunnel-like subaortic stenosis after congenital heart disease operations: A 7-year, single-center experience in 25 patients. 61
31765039 2020
26
Left ventricular apical pacing in children: feasibility and long-term effect on ventricular function. 61
31808515 2020
27
Epicardial Pacemaker in Neonates and Infants: Is There a Relationship Between Patient Size, Device Size, and Wound Complicatıon? 61
32008060 2020
28
Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype. 61
31519519 2020
29
The many faces of early repolarization syndrome: A single-center case series. 61
31521808 2020
30
Midterm outcome of aortic valve neocuspidization for aortic valve stenosis with small annulus. 61
32008187 2020
31
Permanent atrioventricular block after flecainide testing. 61
31631050 2020
32
Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes. 61
31982331 2020
33
Dynamic changes in electrocardiograms of a premature infant with hyperkalemia and hypocalcemia. 61
32023498 2020
34
Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population. 61
32000831 2020
35
Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene. 61
31949022 2020
36
Rare Association of Takotsubo Cardiomyopathy with Right Bundle Branch Block in the Dual Setting of Asthma Exacerbation and Psychiatric Illness. 61
31959739 2020
37
First-in-Human Experience With Patient-Specific Computer Simulation of TAVR in Bicuspid Aortic Valve Morphology. 61
31629752 2020
38
A single-centre cohort and short-term follow-up of patients who developed persistent new onset left bundle branch block after transcatheter aortic valve replacement. 61
31984845 2020
39
Nortriptyline serum concentration as a predictor for cardiac risk in amitriptyline-treated patients. 61
31641787 2020
40
Sevoflurane with opioid or dexmedetomidine infusions in dogs undergoing intracranial surgery: a retrospective observational study. 61
31940687 2020
41
A meta-analysis of perventricular device closure of doubly committed subarterial ventricular septal defects. 61
31992348 2020
42
Transcatheter closure of a perimembranous ventricular septal defect with Nit-Occlud Lê VSD Coil: A French multicentre study. 61
31982353 2020
43
Transcatheter closure of atrial septal defect in symptomatic children weighing ≤10 kg: Addressing unanswered issues from a decade of experience. 61
32030029 2020
44
Prognosis and risk stratification in cardiac sarcoidosis patients with preserved left ventricular ejection fraction. 61
31277963 2020
45
[Lung Cancer Accompanied by Sarcoidosis with Mediastinal and Bilateral Hilar Lymphadenopathy;Report of a Case]. 61
31956253 2020
46
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. 61
31948278 2020
47
[Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review]. 61
31983550 2020
48
Long-Term Electrocardiographic Changes and Clinical Outcomes of Transcatheter Aortic Valve Implantation Recipients Without New Postprocedural Conduction Disturbances. 61
31732136 2020
49
Different dynamics of new-onset electrocardiographic changes after balloon- and self-expandable transcatheter aortic valve replacement: Implications for prolonged heart rhythm monitoring. 61
32007908 2020
50
Usefulness of an Implantable Loop Recorder in Diagnosing Unexplained Syncope and Predictors for Pacemaker Implantation. 61
31920017 2020

Variations for Atrioventricular Block

ClinVar genetic disease variations for Atrioventricular Block:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SCN5A NM_198056.2(SCN5A):c.4783G>A (p.Asp1595Asn)SNV Pathogenic/Likely pathogenic 9385 rs137854607 3:38595800-38595800 3:38554309-38554309
2 SCN5A NM_198056.2(SCN5A):c.892G>A (p.Gly298Ser)SNV Uncertain significance 9387 rs137854608 3:38651267-38651267 3:38609776-38609776

Expression for Atrioventricular Block

Search GEO for disease gene expression data for Atrioventricular Block.

Pathways for Atrioventricular Block

Pathways related to Atrioventricular Block according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.38 TTN TBX5 SCN5A SCN1A NKX2-5 KCNQ1
2
Show member pathways
12.34 SCN5A NPPB MYH7 KCNQ1 KCNE1 GATA4
3
Show member pathways
12.27 TBX5 NPPB NKX2-5 MYH7 GATA4
4 12.15 KCNQ1 KCNH2 KCNE2 KCNE1
5
Show member pathways
11.53 SCN5A SCN1A KCNQ1 KCNE2 KCNE1
6 11.35 TBX5 SCN5A NKX2-5 GATA4
7 11.3 TBX5 NKX2-5 GATA4
8 10.92 SCN5A LMNA KCNQ1 KCNH2 KCNE2 KCNE1
9 10.86 KCNQ1 KCNE1 HCN4
10 10.8 NPPB NKX2-5 MYH7 GATA4
11 10.26 NKX2-5 GATA4

GO Terms for Atrioventricular Block

Cellular components related to Atrioventricular Block according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated sodium channel complex GO:0001518 9.26 SCN5A SCN1A
2 voltage-gated potassium channel complex GO:0008076 9.26 KCNQ1 KCNH2 KCNE2 KCNE1
3 sodium channel complex GO:0034706 9.16 TRPM4 SCN1A
4 Z disc GO:0030018 9.1 TTN SCN5A SCN1A MYH7 KCNE1 CRYAB

Biological processes related to Atrioventricular Block according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 10.13 TRPM4 SCN5A SCN1A KCNQ1 KCNH2 HCN4
2 ion transport GO:0006811 10.13 TRPM4 SCN5A SCN1A KCNQ1 KCNH2 KCNE2
3 potassium ion transport GO:0006813 9.96 KCNQ1 KCNH2 KCNE2 KCNE1 HCN4
4 potassium ion transmembrane transport GO:0071805 9.95 KCNQ1 KCNH2 KCNE2 KCNE1 HCN4
5 muscle contraction GO:0006936 9.92 TTN MYH7 HCN4 CRYAB
6 regulation of membrane potential GO:0042391 9.91 TRPM4 SCN1A KCNH2 HCN4
7 regulation of ion transmembrane transport GO:0034765 9.91 SCN5A SCN1A KCNQ1 KCNH2 KCNE2 KCNE1
8 sodium ion transmembrane transport GO:0035725 9.85 SCN5A SCN1A HCN4
9 cellular response to drug GO:0035690 9.85 KCNQ1 KCNH2 KCNE2
10 cellular response to cAMP GO:0071320 9.84 KCNQ1 KCNE1 HCN4
11 potassium ion import across plasma membrane GO:1990573 9.82 KCNH2 KCNE2 HCN4
12 regulation of heart rate GO:0002027 9.81 SCN5A MYH7 HCN4
13 cardiac muscle cell action potential involved in contraction GO:0086002 9.8 SCN5A SCN1A KCNE2 KCNE1
14 cardiac muscle cell differentiation GO:0055007 9.78 TBX5 NKX2-5 GATA4
15 potassium ion export across plasma membrane GO:0097623 9.78 KCNQ1 KCNH2 KCNE2 KCNE1
16 regulation of potassium ion transmembrane transport GO:1901379 9.77 KCNH2 KCNE2 KCNE1
17 membrane depolarization during action potential GO:0086010 9.77 SCN5A SCN1A KCNH2
18 positive regulation of potassium ion transmembrane transport GO:1901381 9.76 KCNQ1 KCNH2 KCNE1
19 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.76 KCNQ1 KCNH2 KCNE2 KCNE1
20 atrial septum morphogenesis GO:0060413 9.75 TBX5 NKX2-5 GATA4
21 regulation of membrane repolarization GO:0060306 9.74 KCNQ1 KCNH2 KCNE2
22 membrane repolarization GO:0086009 9.73 KCNQ1 KCNH2 KCNE2 KCNE1
23 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.72 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
24 cardiovascular system development GO:0072358 9.71 NKX2-5 KCNQ1
25 positive regulation of sodium ion transport GO:0010765 9.71 SCN5A NKX2-5
26 striated muscle contraction GO:0006941 9.71 TTN MYH7
27 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.71 KCNQ1 KCNH2 KCNE1
28 membrane repolarization during action potential GO:0086011 9.71 KCNQ1 KCNH2 KCNE2 KCNE1
29 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.7 KCNE2 KCNE1
30 sodium ion import across plasma membrane GO:0098719 9.7 TRPM4 HCN4
31 cardiac muscle tissue morphogenesis GO:0055008 9.7 TTN NKX2-5
32 adult heart development GO:0007512 9.7 NKX2-5 MYH7
33 regulation of cardiac muscle cell contraction GO:0086004 9.69 SCN5A GATA4
34 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.69 SCN5A HCN4
35 endocardial cushion development GO:0003197 9.69 TBX5 GATA4
36 positive regulation of cardioblast differentiation GO:0051891 9.69 TBX5 NKX2-5 GATA4
37 ventricular cardiac muscle cell development GO:0055015 9.68 NKX2-5 LMNA
38 cardiac ventricle morphogenesis GO:0003208 9.68 NKX2-5 GATA4
39 atrial cardiac muscle cell action potential GO:0086014 9.68 SCN5A KCNQ1
40 regulation of delayed rectifier potassium channel activity GO:1902259 9.67 KCNE2 KCNE1
41 SA node cell action potential GO:0086015 9.66 SCN5A HCN4
42 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.66 SCN5A KCNQ1
43 membrane depolarization during SA node cell action potential GO:0086046 9.65 SCN5A HCN4
44 membrane depolarization during AV node cell action potential GO:0086045 9.65 TRPM4 SCN5A
45 ventricular cardiac muscle cell action potential GO:0086005 9.65 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
46 membrane depolarization during bundle of His cell action potential GO:0086048 9.63 TRPM4 SCN5A
47 membrane depolarization during Purkinje myocyte cell action potential GO:0086047 9.63 TRPM4 SCN5A
48 cardiac conduction GO:0061337 9.63 TRPM4 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
49 bundle of His development GO:0003166 9.62 TBX5 NKX2-5
50 cardiac muscle contraction GO:0060048 9.43 TTN SCN5A NKX2-5 MYH7 KCNQ1 KCNH2

Molecular functions related to Atrioventricular Block according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.83 TTN TRPM4 SCN5A MYH7 KCNQ1
2 ion channel binding GO:0044325 9.8 SCN5A KCNQ1 KCNE2 KCNE1
3 ion channel activity GO:0005216 9.8 TRPM4 SCN5A SCN1A KCNH2 HCN4
4 scaffold protein binding GO:0097110 9.69 SCN5A KCNQ1 KCNH2
5 sodium channel activity GO:0005272 9.65 SCN5A SCN1A HCN4
6 potassium channel activity GO:0005267 9.65 KCNQ1 KCNH2 KCNE2 KCNE1 HCN4
7 voltage-gated sodium channel activity GO:0005248 9.63 SCN5A SCN1A HCN4
8 delayed rectifier potassium channel activity GO:0005251 9.62 KCNQ1 KCNH2 KCNE2 KCNE1
9 voltage-gated potassium channel activity GO:0005249 9.55 KCNQ1 KCNH2 KCNE2 KCNE1 HCN4
10 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.54 KCNQ1 KCNH2 KCNE1
11 telethonin binding GO:0031433 9.52 TTN KCNE1
12 voltage-gated ion channel activity GO:0005244 9.43 SCN5A SCN1A KCNQ1 KCNH2 KCNE2 HCN4
13 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 8.92 KCNQ1 KCNH2 KCNE2 KCNE1

Sources for Atrioventricular Block

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....